BRIEF published on 10/13/2025 at 14:52, 11 months 6 days ago Crossing of Thresholds by Invus Public Equities in MAAT PHARMA Voting Rights Crossing Thresholds Transfer Of Shares MaaT Pharma Invus Public Equities
BRIEF published on 10/06/2025 at 14:59, 11 months 13 days ago Symbiosis LLC Reduces Stake in MAAT PHARMA Voting Rights Crossing Thresholds Transfer Of Shares MaaT Pharma Symbiosis LLC
BRIEF published on 09/17/2025 at 07:35, 1 year ago MaaT Pharma unveils its 2025 half-year results Revenue Growth Half-year Results EIB Financing MaaT013 Efficiency Clinigen Agreement
PRESS RELEASE published on 09/17/2025 at 07:30, 1 year ago Inside Information / Information on annual revenues MaaT Pharma presents positive Half Year 2025 Results with promising data from Phase 3 trial of MaaT013 in aGvHD. Company strengthens position with partnerships and financing Partnerships Phase 3 Trial Half Year Results MaaT Pharma AGvHD
BRIEF published on 07/28/2025 at 07:35, 1 year 1 month ago MaaT Pharma Secures €37.5 Million Loan to Boost Hemato-Oncology Programs Clinical Development EIB Loan Hemato-oncology Microbiome Therapy Xervyteg® Approval
PRESS RELEASE published on 07/28/2025 at 07:30, 1 year 1 month ago Inside Information / Other news releases MaaT Pharma secures €37.5 million loan from the European Investment Bank to advance clinical programs in Hemato-Oncology. Funding supports late-stage assets Xervyteg® and MaaT033 European Investment Bank Clinical Programs Loan MaaT Pharma Hemato-oncology
BRIEF published on 06/24/2025 at 20:05, 1 year 2 months ago MaaT Pharma General Meeting: Results and Appointments Kepler Cheuvreux Resolutions General Assembly MaaT Pharma Appointment Of President
PRESS RELEASE published on 06/24/2025 at 20:00, 1 year 2 months ago Inside Information / Other news releases MaaT Pharma presents Annual General Meeting results, with shareholders approving most resolutions. Jean-Marie Lefevre appointed Chairman. Liquidity contract with Kepler Cheuvreux maintained Annual General Meeting Shareholders Liquidity Contract MaaT Pharma Jean-Marie Lefevre
BRIEF published on 06/19/2025 at 19:05, 1 year 3 months ago MaaT Pharma Advances Xervyteg® Commercialization Efforts European Market Clinical Trials Oncology Microbiome Xervyteg®
PRESS RELEASE published on 06/19/2025 at 19:00, 1 year 3 months ago Inside Information / Other news releases MaaT Pharma provides business update & highlights key milestones for 2025, including MA application submission for Xervyteg, strategic focus in Europe & US trial launch Business Update Clinical-stage Biotechnology MaaT Pharma Key Milestones Xervyteg
Published on 09/19/2026 at 00:55, 23 hours 3 minutes ago Gossan Resources Announces Changes to Board and Management
Published on 09/18/2026 at 22:00, 1 day 1 hour ago Silver Tiger Announces Results of Annual and Special Meeting
Published on 09/18/2026 at 20:35, 1 day 3 hours ago Only 11% of Marketers Expect Google Search to Be Their Customers' Main Starting Point in Two Years
Published on 09/18/2026 at 14:30, 1 day 9 hours ago AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement
Published on 09/19/2026 at 16:40, 7 hours 17 minutes ago 2026 Cross-Strait (Kunshan) Mid-Autumn Lantern Festival Opens
Published on 09/19/2026 at 13:15, 10 hours 43 minutes ago Eurobattery Minerals AB has received information regarding court judgment and criminal suspicion concerning the CEO
Published on 09/19/2026 at 07:30, 16 hours 28 minutes ago Hong Kong sets out initiatives to secure long-term development of pillar industries
Published on 09/18/2026 at 18:44, 1 day 5 hours ago EQS-Adhoc: Enapter AG announces preliminary, unaudited figures for the first half of 2026 and restructures its US sales operations – one-off expense of EUR 17 million
Published on 09/18/2026 at 18:34, 1 day 5 hours ago Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/17/2026 at 17:40, 2 days 6 hours ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
